Surgical management of HIV-associated lipodystrophy: Role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy

Annals of Plastic Surgery

Volumn 58, Issue 3, 2007, Pages 255-263

  Hultman, C Scott ^a   McPhail, Lindsee E ^a   Donaldson, Jeffrey H ^a   Wohl, David A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

HAART; HIV lipodystrophy; Lipoatrophy; Lipohypertrophy; Liposuction

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; AZATHIOPRINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DISEASE DURATION; ECCHYMOSIS; EYELID RECONSTRUCTION; FEMALE; FOLLOW UP; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; LIPECTOMY; LIPOHYPERTROPHY; LIPOSUCTION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; RHYTIDOPLASTY; SURGICAL PATIENT; SURGICAL TECHNIQUE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; WEIGHT GAIN;

ADIPOSE TISSUE; ADULT; DEMOGRAPHY; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERTROPHY; LIPECTOMY; MALE; MIDDLE AGED; PREOPERATIVE CARE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34247625040     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000248128.33465.83     Document Type: Review

References (47)

1. Carr A, Samaras K, Chisolm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
2. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006;43:645-655.
3. Garg A. Lipodystrophies. Am J Med. 2000;108:143-152.
4. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
5. Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis. 2004;17:27-32.
6. Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis. 2005;18:25-33.
7. Jones D. HIV facial lipoatrophy: causes and treatment options. Dermatol Surg. 2005;31:1519-1529.
8. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg. 2002;28:979-986.
9. Bacchetti P, Gripshover B, Grunfeld C, et al. Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131.
10. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2003;34:461-466.
11. Krause JC, Toye MP, Stechenberg BW, et al. HIV-associated lipodystrophy in children. Pediatr Endocrinol Rev. 2005;3:45-51.
12. Gold DR, Annino DJ Jr. HIV-associated cervicodorsal lipodystrophy: etiology and management. Laryngoscope. 2005;115:791-795.
13. Guaraldi G, Orlando G, Murri R, et al. Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res. 2006;15:173-178.
14. Power R, Tate HL, McGill SM, et al. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect. 2003;79:137-141.
15. Wohl DA. Editorial comment: correcting facial lipoatrophy has little to do with vanity. AIDS Read. 2005;15:372.
16. Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Read. 2005;15:369-375.
17. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39:395-400.
18. Moyle GJ. Plastic surgical approaches for HIV-associated lipoatrophy. Curr HIV/AIDS Rep. 2005;2:127-131.
19. Abood A, Ong J, Withey S, et al. Facial atrophy in HIV-related fat redistribution syndrome: a plastic surgical perspective on treatment options and a look to the future. Int J STD AIDS. 2006;17:217-220.
20. Serra-Renom JM, Fontdevila J. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg. 2004;114:551-555; discussion 556-557.
21. Burnouf M, Buffet M, Schwarzinger M, et al. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique. Arch Dermatol. 2005;141:1220-1224.
22. Guaraldi G, De Fazio D, Orlando G, et al. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis. 2005;40:e13-e15.
23. Strauch B, Baum T, Robbins N. Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg. 2004;113:363-370; discussion 371-372.
24. Wechselberger G, Sarcletti M, Meirer R, et al. Dermis-fat graft for facial lipodystrophy in HIV-positive patients: is it worthwhile? Ann Plast Surg. 2001;47:99-100.
25. Benito-Ruiz J, Fontdevila J, Manzano M, et al. Hip and buttock implants to enhance the feminine contour for patients with HIV. Aesthetic Plast Surg. 2006;30:98-103.
26. Funk E, Bressler FJ, Brissett AE. Contemporary surgical management of HIV-associated facial lipoatrophy. Otolaryngol Head Neck Surg. 2006;134:1015-1022.
27. Hodgkinson DJ. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg. 2003;50:328.
28. Talmor M, Hoffman LA, LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg. 2002;49:11-17; discussion 117-118.
29. Binder WJ, Bloom DC. The use of custom-designed midfacial and submalar implants in the treatment of facial wasting syndrome. Arch Facial Plast Surg. 2004;6:394-397.
30. Silvers SL, Eviatar JA, Echavez MI, et al. Prospective, open-label 18-month trial of calcium hydroxyapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg. 2006;118(suppl):34S-45S.
31. Lam SM, Aizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg. 2006;118(suppl):55S-63S.
32. Valantin M, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-2477.
33. Ponce-de-Leon S, Iglesias M, Ceballos J, et al. Liposuction for proteaseinhibitor-associated lipodystrophy. Lancet. 1999;353:1244.
34. Wolfort FG, Cetrulo CL, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg. 1999;104:1814-1820.
35. Rohrich RJ, Kenkel JM. Invited discussion: suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg. 1999;104:1821-1822.
36. Chastain MA, Chastain JB, Coleman WP. HIV lipodystrophy: review of the syndrome and report of a case treated with liposuction. Dermatol Surg. 2001;27:497-500.
37. Gervasoni C, Ridolfo AL, Rovati L, et al. Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement. AIDS Patient Care STDS. 2002;16:307-311.
38. DeWeese JE, Delaney AR, Klein D, et al. UAL of HIV lipohypertrophy of the head and neck. Presented at the Poster Session of the Annual Scientific Meeting of the American Society of Plastic Surgeons, San Diego, CA, October 25-29, 2003 and published in Plastic Surgical Forum. 2003;XXVI:317-318.
39. Piliero PJ, Hubbard M, King J, et al. Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. CID HIV/AIDS. 2003;37:1374-1377.
40. Gervasoni C, Ridolfo AL, Vaccarezza M, et al. Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. AIDS. 2004;18:574-576.
41. Connolly N, Manders E, Riddler S. Suction-assisted lipectomy for lipodystrophy. AIDS Res Hum Retroviruses. 2004;20:813-815.
42. The Global HIV/AIDS pandemic, 2006. MMWR Morb Mortal Wkly Rep. 2006;55:841-844.
43. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36:795-802.
44. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
45. Buffet M, Schwarzinger M, Amellal B, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol. 2005;33:60-64.
46. Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2005;38:263-267.
47. Roge BT, Calbet JA, Moller K, et al. Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels. AIDS. 2002;16:973-982.